Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III, Randomized, Open-Label, Multicenter Study Evaluating the Efficacy and Safety of Divarasib Versus Sotorasib or Adagrasib in Patients With Previously Treated KRAS G12C-Positive Advanced or Metastatic Non-Small Cell Lung Cancer

NCT06497556 is registered in ClinicalTrials.gov with Hoffmann-La Roche as lead sponsor.

NCT NCT06497556
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06497556 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III, Randomized, Open-Label, Multicenter Study Evaluating the Efficacy and Safety of Divarasib Versus Sotorasib or Adagrasib in Patients With Previously Treated KRAS G12C-Positive Advanced or Metastatic Non-Small Cell Lung Cancer
Lead sponsor
Hoffmann-La Roche
Phase
Phase 3
Overall status
Active, not recruiting
Start date
September 23, 2024
Completion date
November 30, 2029
Enrollment
338 (actual)
Sites
151

Conditions

As the registry lists them; a condition with its own page is linked.

kras g12c lung cancer, non-small cell lung cancer